Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
Big pharma companies eagerly await key decisions on drugs from the FDA next week.
Breakthrough designation will help faster review of Rituxan for treating rare disease Pemphigus Vulgaris
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||31.77 - 32.03|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.11|
|Dividend & Yield||1.02 (3.21%)|
|1y Target Est||N/A|